Neurol. praxi. 2021;22(5):395-397 | DOI: 10.36290/neu.2021.067
Ocrelizumab - clinical evaluation and disease progression - 6,5 years data
- Neurologické oddělení, KNTB, Zlín
The treatment of multiple sclerosis has undergone great progress in recent years. With the advent of new drugs, our therapeutic possibilities are expanding. The therapeutic goal remains the stability of the disease, which is monitored in clinical practice by controlling the signs of attack or disease progression. This article discusses new data on clinical activity and effects on disease progression in patients treated with ocrelizumab.
Keywords: multiple sclerosis, ocrelizumab, ARR, CDP.
Received: August 10, 2021; Revised: August 10, 2021; Accepted: September 11, 2021; Prepublished online: September 11, 2021; Published: November 8, 2021 Show citation
References
- Giovannoni G, Kappos L, Seze JD, Hauser SL, Overell J, Koendgen H, Schneble HM, Prajapati K, Wang Q, Wolinsky JS. Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS. P0216. ECTRIMS. Washington D.C., US 2020.
Go to original source... - Hauser SL, Bar Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, for the OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. NEJM Org., December 21, 2016. doi: 10.1056/NEJMoa1601277. Go to original source...
Go to PubMed... - Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, Thompson AJ, Wolinski JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O´Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis the 2013 revision. Neurology 2014; 83: 278-286. Go to original source... Go to PubMed...
- Lycke J. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Ther Adv Neurol Disord. 2015; 8(6): 274-293. Go to original source... Go to PubMed...
- SPC Ocrevus. Dostupné www.sukl.cz, www.sukl.sk.
- Thompson AJ, Banwell BL Barkhof F, Carrol WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revision of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162-173. Go to original source... Go to PubMed...